Temporal trends in relative survival of diffuse large B‐cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies

作者：Sara Harrysson, Sandra Eloranta, Stefanie Antonilli, Mikkel Runason Simonsen, Kristina Sonnevi, Peter de Nully Brown, Björn E. Wahlin, Per‐Ola Andersson, Judit Jørgensen, Mats Jerkeman, Christian Bjørn Poulsen, Gunilla Enblad, Tarec Christoffer El‐Galaly, Karin E. Smedby · 发表于：British Journal of Haematology · 年份：2025 · DOI：10.1111/bjh.20104 · 被引用次数：3 · 研究领域：CAR-T cell therapy research、Lymphoma Diagnosis and Treatment、Acute Lymphoblastic Leukemia research

Diffuse large B-cell lymphoma (DLBCL) is a B-cell neoplasm characterized by an aggressive clinical course.1 Approximately one-fourth of the patients starting primary treatment with curative intent are treatment refractory or relapse during the initial follow-up and subsequently have a much worse prognosis.2, 3 New targeted and cellular therapies have shown unprecedented response rates and duration of responses in relapsed/refractory DLBCL.4-6 In Sweden, CAR (chimaeric antigen receptor) T-cell therapy was approved in 2019, but in Denmark, a neighbouring country with a similar health-care structure, CAR T was not approved until 2023. Bispecific antibodies (i.e. glofitamab, epcoritamab) have been available from 2017 to 2018 and onwards in clinical trials in both countries, but are not yet approved for routine use.7, 8 In this study, we aimed to assess temporal trends in survival among DLBCL patients in Sweden and Denmark overall with special focus on the most recent calendar period when CAR T was approved in Sweden but not in Denmark. We identified all DLBCL patients ≥18 years (ICD-O/3: 96783 96803 96883 97123 97373 97383 97353) in the Swedish Lymphoma Register (SLR) (n = 9343) and the Danish Lymphoma Register (LYFO) (n = 6709) diagnosed 2007–2021. Patients with transformed indolent lymphomas were excluded. SLR and LYFO are national quality-of-care registers that contain detailed information regarding lymphoma characteristics, treatment and survival.9, 10 During the study period...